Genetic Risk of Diverticular Disease Predicts Early Stoppage of Nicorandil.

Clinical Pharmacology and Therapeutics
James D NoyesChim C Lang

Abstract

Gastrointestinal fistulation has been widely reported as an adverse effect of nicorandil therapy in Europe. People who have underlying diverticular disease are most at risk of this side effect. In Western countries, diverticular disease is highly prevalent and can be clinically silent. This study aimed to identify diverticular disease genetic risk scores (GRSs) associated with early nicorandil stoppage, a surrogate marker for drug intolerance. A case-control study was carried out on 1,077 patients from the Genetics of Diabetes Audit and Research Tayside Scotland (GoDARTS) database. Cases were defined as having < 9 nicorandil prescriptions with no identifiable reason for stopping (n = 230). Controls had either ≥ 9 prescriptions, treatment continuation to death/study end or stoppage post-myocardial infarction. Two diverticular GRSs were created and used in logistic regression models. Isosorbide mononitrate was used as a control analysis. Patients with a raised diverticular GRS, based on 23 replicable loci, had increased risk of stopping nicorandil therapy early (univariate (odds ratio (OR) 2.26; P = 0.04], multivariate (OR 3.96; P = 0.01)). Similar trends were noted when using the full 42 variant diverticular score but statistica...Continue Reading

References

Feb 1, 1970·Archives of Environmental Health·G N Stemmermann
Jul 9, 2005·European Journal of Gastroenterology & Hepatology·Shanmugarajah Rajendra, Jacqueline J Ho
Oct 20, 2005·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·R J L F Loffeld
Jul 25, 2008·The New England Journal of Medicine·UNKNOWN SEARCH Collaborative GroupR Collins
Sep 8, 2010·Annals of the Royal College of Surgeons of England·James McDaidAdrian P Savage
Aug 31, 2011·Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie·Adam V Weizman, Geoffrey Christopher Nguyen
Mar 22, 2012·Alimentary Pharmacology & Therapeutics·J GranlundP Thelin Schmidt
Mar 31, 2012·International Wound Journal·Philippe TrechotAnnick Barbaud
May 13, 2017·Gut and Liver·Mona RezapourNeil Stollman
Oct 13, 2017·International Journal of Epidemiology·Harry L HébertColin N A Palmer
Apr 24, 2019·Clinical Pharmacology and Therapeutics·Ewan R Pearson
Sep 11, 2019·European Heart Journal·Juhani KnuutiUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Citations

Mar 27, 2021·Clinical Case Reports·James D NoyesChim C Lang
Dec 26, 2021·Clinical Pharmacology and Therapeutics·Danielle JohnsonBritt I Drögemöller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Related Papers

Annals of the Royal College of Surgeons of England
James McDaidAdrian P Savage
Journal of the Indian Medical Profession
I P Todd
Acta Gastro-enterologica Belgica
A M Connell
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
A N Allan
Deutsche medizinische Wochenschrift
W Vogt, J Schölmerich
© 2022 Meta ULC. All rights reserved